BCAL Diagnostics (ASX:BDX) Beginning Cash Position: A$4.52 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BCAL Diagnostics Beginning Cash Position?

BCAL Diagnostics ASX:BDX +2.82% Beginning Cash Position is A$4.52 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

BCAL Diagnostics's Beginning Cash Position for the quarter that ended in Dec. 2025 was A$4.52 Mil.

BCAL Diagnostics's quarterly Beginning Cash Position increased from Dec. 2024 (A$6.47 Mil) to Jun. 2025 (A$7.01 Mil) but then declined from Jun. 2025 (A$7.01 Mil) to Dec. 2025 (A$4.52 Mil).

BCAL Diagnostics's annual Beginning Cash Position declined from Jun. 2023 (A$5.57 Mil) to Jun. 2024 (A$3.17 Mil) but then increased from Jun. 2024 (A$3.17 Mil) to Jun. 2025 (A$6.47 Mil).

BCAL Diagnostics Beginning Cash Position Related Terms

BCAL Diagnostics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for BCAL Diagnostics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics Beginning Cash Position Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Beginning Cash Position
3.41 5.57 3.17 6.47

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.17 5.02 6.47 7.01 4.52

BCAL Diagnostics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of A$4.52 Mil mean?
BCAL Diagnostics (ASX:BDX) has a Beginning Cash Position of A$4.52 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on BCAL Diagnostics and its competitors.
Is BCAL Diagnostics' Beginning Cash Position too high?
BCAL Diagnostics' current Beginning Cash Position is A$4.52 Mil.
How does BCAL Diagnostics' Beginning Cash Position compare to TMO and DHR?
BCAL Diagnostics' Beginning Cash Position of A$4.52 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Diagnostics & Research company?
A good Beginning Cash Position depends on the Medical Diagnostics & Research industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on BCAL Diagnostics and its competitors. BCAL Diagnostics's current Beginning Cash Position is A$4.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Beginning Cash Position of A$4.52 Mil. The current Beginning Cash Position is A$4.52 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Beginning Cash Position is A$4.52 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.